This is of particular importance in HNSCC, since enhanced EGFR signalling/expression has been associated with aggressive disease and poor prognosis (Dassonville et al, 1993; Grandis and Tweardy, 1993; Kalyankrishna and Grandis, 2006) and EGFR-targeted molecular therapeutics are currently being examined in clinical settings (for recent reviews, see Astsaturov et al, 2006a, 2006b and Reuter et al, 2007). This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.